Travere Therapeutics Inc

NASDAQ:TVTX   3:59:51 PM EDT
26.09
-1.45 (-5.26%)
Products

Travere Therapeutics Announces Positive Topline Results from the Ongoing Phase 1/2 Study of Pegtibatinase in Classical Homocystinuria

Published: 12/15/2021 13:31 GMT
Travere Therapeutics Inc (TVTX) - Travere Therapeutics Announces Positive Topline Results From the Ongoing Phase 1/2 Compose Study of Pegtibatinase in Classical Homocystinuria.
Travere - Results Provide Clinical Proof of Concept for First Potential Therapy Targeting Underlying Enzyme Deficiency in Classical Homocystinuria.
Travere Therapeutics Inc - Treatment With Highest Dose Pegtibatinase Led to a Clinically Meaningful 55% Mean Reduction in Total Homocysteine From Baseline.
Travere Therapeutics Inc - to Date in Study, Pegtibatinase Has Been Generally Well-tolerated.